Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27601700 | 0.79 | GAA (0.35) | GAAKMT2A | |
| SCHEMBL6790445 | 0.68 | GAA (0.42) | GAAKMT2A | |
| SCHEMBL2443752 | 0.67 | GAA (0.46) | GAAKMT2A | |
| SCHEMBL18190317 | 0.63 | GAA (0.43) | GAAKMT2A | |
| SCHEMBL8927868 | 0.60 | CYP3A4 (0.40) | GAAKMT2A | |
| SCHEMBL27449226 | 0.59 | GAA (0.55) | GAAKMT2A | |
| SCHEMBL3786708 | 0.58 | GAA (0.52) | GAAKMT2A | |
| SCHEMBL23693425 | 0.57 | KDM1A (0.35) | GAA | |
| SCHEMBL8762100 | 0.57 | MAPT (0.33) | GAA | |
| SCHEMBL3841879 | 0.57 | CYP3A4 (0.48) | GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747051-B2 | BLADDER UROGENITAL DISORDERS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-08 | — | — | US | disclosed |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6602897-B2 | For example, 2-((2-bromo-3-chloro-5-dimethylamino-6-methylphenyl)imino)imid azolidine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1328517-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002032876-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | RXFP1, RXFP3, PRMT1 | GAA 4530/4885KMT2A 1573/4885 |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | HRH2, RXFP3, AREG | GAA 3387/4885KMT2A 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.